Form 4: AIM ImmunoTech CEO Buys Shares
Insider Transaction (Form 4)
Thomas K Equels, CEO & President and a Director of AIM ImmunoTech Inc., purchased 11,000 shares of common stock on September 16, 2026 for $0.21 per share.
Summary
- Open-market purchase: acquired 11,000 Common Stock at $0.21 ($2,310) on September 16, 2026; holds 102,822 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $2,310, committing personal capital to the stock.
Insider Transactions
Thomas K Equels — Director, Officer (CEO & President)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-16 | Open-market purchase | Common Stock | 11,000 | $0 | $2.3K | 102,822 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-16 | Open-market purchase (11,000 shares) |
Keywords
insider transaction, Form 4, AIM, AIM ImmunoTech Inc., bullish, Thomas K Equels
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.